Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos Rovi reported earnings per share of 0.34 USD for the quarter ended June 30, 2026, compared with 0.10 USD in the year-ago quarter. Revenue increased 23.11% to 222.9 million USD from 181.0 million USD a year earlier. No further operational details were provided. » Więcej na finanzen.net

ROVI reported Q1 2026 revenue of 152.5 million EUR, coming in well below expectations and triggering a 22.6% share price drop. Revenue was weighed down mainly by weakness in the heparin division, while gross margin rose to 62.3%. EBITDA was 20.3 million EUR (margin 13.3%), and net income was 9.4 million EUR. The company adjusted its full-year outlook to low- to mid-single-digit revenue growth and cited delays in CDMO contracts as a risk; OKEDI, however, showed strong sales growth. » Więcej na de.investing.com

Rovi reports for Q1 2026 a revenue decline of 1.5% to €152.5m while gross margin increased to 62.3%. Despite strong momentum at Okedi® (+37%) and 5% growth in the CDMO business, EBITDA, EBIT and net profit fell sharply as SG&A rose 18% and R&D increased 79%. The company is strengthening its CDMO presence with the acquisition of a facility in Phoenix, proposes a dividend and expects 2026 revenue growth in the low- to mid-single-digit percentage range, while NMH remains under pressure. » Więcej na de.investing.com

ROVI reported Q1 2026 revenue of €154.7m, flat year on year, a gross profit of €95m (+5%) and an improved gross margin of 62.3% (+3.8 percentage points). The heparin division contracted by 12%, while specialty pharmaceutical Okedi increased sales by 37%. R&D expenses rose sharply by 79%; EBITDA was €20.3m (margin 13.3%) and net profit €9.4m. ROVI expects moderate revenue growth for 2026 in the low- to mid-single-digit range but warns of risks from pressure in the heparin market and delays in manufacturing agreements. » Więcej na de.investing.com

ROVI has lowered its 2026 sales forecast and now expects operational sales growth in the low- to mid-single-digit percentage range. The reasons are reduced orders under an agreement with a global pharmaceutical company and ongoing price pressure in the heparin business. In Q1, operational sales fell 1.5% to €152.5m and EBITDA fell 33% to €20.3m, with the EBITDA margin dropping to 13.3%. ROVI reports a decline in heparin sales, growth at Okedi, and completed the acquisition of a manufacturing site in Phoenix; two multinational studies for Risperidon QUAR are planned. » Więcej na de.investing.com